Beijing Firm Launches Clinical Trial On Stem Cell Treatment For Diabetes
This article was originally published in PharmAsia News
BEIJING - The chief executive officer of the Beijing-headquartered firm Cellonis says that preliminary results from an ongoing clinical trial in the Chinese capital are a promising sign of the potential for widening use of a stem cell-based treatment for diabetes in the future
You may also be interested in...
GSK VP Paul Bolno on market-specific opportunities in Asia.
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
China At Ground Zero In Explosion of New Diabetes Cases; International Federation Now Projects 500 Million Diabetics Worldwide By 2030
BEIJING - A vast new study conducted by scientists in North America and Asia places China at ground zero in terms of an explosion in the incidence of diabetes, and "shows that the global burden of diabetes is far larger than previously estimated," according to a scholar at the Brussels, Belgium-based International Diabetes Federation